Global Antibacterial Drugs Market Size Likely to Surpass at a CAGR of 5.6% By 2033
Key highlights
- Antibacterial Drugs Market Growth Factors Antimicrobial Resistance (AMR): The rising prevalence of antimicrobial resistance is a significant driver of the market.
- Report Scope Antibacterial Drugs Market: COVID-19 Analysis Increased Antibiotic Use: At the outset of the pandemic, there was a surge in antibiotic prescriptions.
- Healthcare providers faced challenges in implementing antibiotic stewardship programs amidst the urgency of COVID-19 care.
As per the current market research conducted by the CMI Team, the global Antibacterial Drugs Market size is expected to record a CAGR of 5.6% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 51.55 billion. By 2032, the valuation is anticipated to reach USD 67.9 billion.
Antibacterial Drugs Market Growth Factors
- Antimicrobial Resistance (AMR): The rising prevalence of antimicrobial resistance is a significant driver of the market. As bacteria develop resistance to existing antibiotics, there is an urgent need for novel antibacterial drugs to combat these drug-resistant strains.
- Infectious Disease Burden: The global burden of infectious diseases, including bacterial infections, continues to drive demand for antibacterial drugs. The ongoing threat of pandemics and endemic diseases underscores the importance of effective treatments.
- Research and Development: Pharmaceutical companies and research institutions are actively engaged in developing new antibacterial drugs. Investments in R&D are essential to discover innovative therapies that can address emerging resistance patterns.
- Regulatory Initiatives: Regulatory agencies worldwide are promoting antibiotic stewardship programs and providing incentives for the development of novel antibacterial drugs. Expedited pathways for approvals encourage manufacturers to invest in this area.
- Patient Demographics: The aging population, coupled with the vulnerability of certain demographics to bacterial infections, creates a sustained demand for antibacterial treatments.
- Public Health Initiatives: Governments and healthcare organizations are launching public health campaigns to raise awareness about responsible antibiotic use, reducing overprescription, and combating antimicrobial resistance.
- Global Health Security: Infectious diseases pose a global health security threat. The COVID-19 pandemic has emphasized the need for preparedness and the development of treatments for emerging infectious diseases.
- Economic Factors: Economic development, healthcare access, and affordability influence the demand for antibacterial drugs in different regions.
- Combination Therapies: The development of combination therapies that target multiple mechanisms of action and combat drug-resistant strains is a growing trend in the antibacterial drugs market.
- Patient Care Settings: The choice of antibacterial drugs varies depending on the care setting, such as hospitals, outpatient clinics, and community settings, affecting market dynamics.
- Healthcare Infrastructure: The availability and quality of healthcare infrastructure, particularly in low- and middle-income countries, impact the accessibility of antibacterial drugs.
- Environmental Concerns: Environmental factors, such as the release of antibiotics into the environment, are gaining attention due to their potential contribution to antibiotic resistance.
Report Scope
Source: Custom Market Insights analysis.
| Feature of the Report | Details |
| Market Size in 2023 | USD 53.18 Billion |
| Projected Market Size in 2032 | USD 67.9 Billion |
| Market Size in 2022 | USD 51.55 Billion |
| CAGR Growth Rate | 5.6% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Drug Class, Type, Action Mechanism and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Antibacterial Drugs Market: COVID-19 Analysis
- Increased Antibiotic Use: At the outset of the pandemic, there was a surge in antibiotic prescriptions. This was partly due to concerns about secondary bacterial infections in COVID-19 patients and the use of antibiotics as a precautionary measure.
- Antibiotic Stewardship Challenges: The overuse and misuse of antibiotics during the pandemic raised concerns about antibiotic resistance. Healthcare providers faced challenges in implementing antibiotic stewardship programs amidst the urgency of COVID-19 care.
- Supply Chain Disruptions: The pandemic disrupted global supply chains, affecting the production and distribution of pharmaceuticals, including antibiotics. This led to shortages and delays in the availability of certain antibacterial drugs.
- Shift in Research Focus: Some pharmaceutical companies shifted their research efforts toward developing treatments and vaccines for COVID-19. This diversion of resources impacted the development of new antibacterial drugs.
- Telemedicine and Telehealth: Telemedicine and telehealth services witnessed a rapid expansion during the pandemic. Virtual consultations reduced in-person visits to healthcare facilities, affecting antibiotic prescribing patterns.
List of the prominent players in the Antibacterial Drugs Market:
- AbbVie Inc.
- Pfizer Inc.
- Novartis AG
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals Inc.
- Viatris Inc.
- Melinta Therapeutics LLC
- Cipla Inc.
- Shionogi & Co. Ltd.
- KYORIN Pharmaceutical Co. Ltd.
- GSK plc
- Nabriva Therapeutics PLC
- Others
The Antibacterial Drugs Market is segmented as follows:
By Drug Class
- Cephalosporin
- Penicillin
- Fluoroquinolone
- Macrolides
- Carbapenems
- Aminoglycosides
- Sulfonamides
- 7-ACA
- Others
By Type
- Branded Antibiotics
- Generic Antibiotics
By Action Mechanism
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors
- Mycolic Acid Inhibitors
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Veena Jagtap
Sr. Research AnalystResearch Analyst at Custom Market Insights, specializing in market research, competitive analysis, industry trends, and growth opportunities. Focused on transforming complex data into actionable insights that drive strategic decision-making and business growth.
View profile and reportsAbout Custom Market Insights
Custom Market Insights is a market research and advisory company. It publishes syndicated reports across 18+ industries and delivers custom research, feasibility studies and market entry strategy for companies, investors and consultancies.
###
